Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307293 | 0.92 | MEN1 (0.43) | HTR2CMEN1NPC1RAB9AKMT2A | |
| SCHEMBL222040 | 0.88 | HTR2C (0.49) | HTR2CMEN1NPC1RAB9AKMT2A | |
| SCHEMBL2401358 | 0.88 | CYP3A4 (0.55) | HTR2CMEN1NPC1RAB9AKMT2A | |
| SCHEMBL30751773 | 0.88 | CYP3A4 (0.55) | HTR2CMEN1NPC1RAB9AKMT2A | |
| SCHEMBL28981243 | 0.83 | ALDH1A1 (0.52) | MEN1NPC1RAB9AKMT2AHTR3A | |
| SCHEMBL3506845 | 0.79 | NPC1 (0.49) | MEN1NPC1RAB9AKMT2ACHRM1 | |
| SCHEMBL30645420 | 0.79 | NPC1 (0.49) | MEN1NPC1RAB9AKMT2ACHRM1 | |
| SCHEMBL452908 | 0.79 | NPC1 (0.49) | MEN1NPC1RAB9AKMT2ACHRM1 | |
| SCHEMBL6313436 | 0.78 | HTR2C (0.48) | HTR2CHTR3AHTR6CHRM4CHRM5 | |
| SCHEMBL11833898 | 0.78 | CYP3A4 (0.46) | HTR2CMEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131660-B2 | Tetrahydro-azepinoquinolines as agonists of the 5-HT2C receptor | SUNNYLIFE PHARMA, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180215752-A1 | TETRAHYDRO-AZEPINOQUINOLINES AS AGONISTS OF THE 5-HT2C RECEPTOR | SUNNYLIFE PHARMA, INC. (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215752-A1 | TETRAHYDRO-AZEPINOQUINOLINES AS AGONISTS OF THE 5-HT2C RECEPTOR | SUNNYLIFE PHARMA, INC. (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215752-A1 | TETRAHYDRO-AZEPINOQUINOLINES AS AGONISTS OF THE 5-HT2C RECEPTOR | SUNNYLIFE PHARMA, INC. (US) | 2018-08-02 | — | — | US | disclosed |
| WO-2016033228-A1 | TETRAHYDRO-AZEPINOQUINOLINES AS AGONISTS OF THE 5-HT2C RECEPTOR | SUNNYLIFE PHARMA, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033228-A1 | TETRAHYDRO-AZEPINOQUINOLINES AS AGONISTS OF THE 5-HT2C RECEPTOR | SUNNYLIFE PHARMA, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| US-6930185-B2 | Melanin-concentrating hormone antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1285651-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-26 | — | — | EP | disclosed |
| US-3987047-A | ANORETICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | MCHR1, MC1R, MCHR2 | HTR2C 107/4885MEN1 292/4885NPC1 1013/4885 |
| US-10131660-B2 | Tetrahydro-azepinoquinolines as agonists of the 5-HT2C receptor | HTR2C, HTR2A, HTR1A | HTR2C 1/4885MEN1 3485/4885NPC1 3809/4885 |
| US-20180215752-A1 | TETRAHYDRO-AZEPINOQUINOLINES AS AGONISTS OF THE 5-HT2C RECEPTOR | HTR2C, HTR2A, HTR1A | HTR2C 1/4885MEN1 3485/4885NPC1 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.